Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Sartorius Stedim Biotech ( (FR:DIM) ) just unveiled an update.
Sartorius Stedim Biotech has announced the availability of its 2024 Universal Registration Document, which includes the group’s business development details for 2024 and the 2025 forecast. This document, now accessible on their investor relations page, also contains the consolidated financial statements for the year ended December 31, 2024. The release of this document provides stakeholders with comprehensive insights into the company’s financial and strategic positioning, potentially impacting investor confidence and industry standing.
More about Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. The company, headquartered in Aubagne, France, offers innovative solutions for the manufacturing of biotech medications, such as cell and gene therapies. With a strong global presence, the company operates manufacturing and R&D sites, as well as sales entities in Europe, North America, and Asia. Its shares are listed on Euronext Paris, and it regularly broadens its portfolio through strategic acquisitions. In 2024, Sartorius Stedim Biotech reported sales revenue of around 2.8 billion euros, supported by a workforce of over 9,900 employees worldwide.
YTD Price Performance: 13.73%
Average Trading Volume: 37,999
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €20.54B
Learn more about DIM stock on TipRanks’ Stock Analysis page.
